Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 827 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Weak Immunogenicity in Patients with Cancer After First Dose of mRNA-based... May 18, 2021 Improving Cancer Immunotherapy: Overcoming the Problem of ‘Exhausted’ T Cells July 18, 2019 Helping Cancer Survivors Cope with Cancer-Related Anxiety and Distress April 30, 2020 Breast Cancer Survivor Driven from Her Home by Noxious Gases from... June 11, 2021 Load more HOT NEWS Patient Guide in Hepatocellular Carcinoma Now Available Also in German Using Integrative Therapies to Help Manage Cancer-Related Pain: An Expert Q&A High-Fat Diet or Diabetes Drug May Enhance Response to Targeted Cancer... How to Cope With Panic Attacks During Cancer
